In view of the limited information available on hearing disorders associated with treatment with INF-α, the purpose of this study was to (1) determine the rate of hearing disorders (tinnitus, hearing loss) in patients with chronic hepatitis who received INF-α; (2) evaluate the level of hearing loss after one month of INF-α treatment; (3) assess the age distribution of hearing disorders due to INF-α usage; and (4) assess the association of gender with hearing disorders due to INF-α usage. The gene discussed is IFNA17; the disease is hearing disorder.